DGAP-News: Cytos Biotechnology receives EU funding to work on novel vaccine approaches for emerging viral diseases
(firmenpresse) - EquityStory AG-News: Cytos Biotechnology AG / Key word(s): Research
Update
Cytos Biotechnology receives EU funding to work on novel vaccine
approaches for emerging viral diseases
21.02.2011 / 07:00
---------------------------------------------------------------------
Schlieren (Zurich), Switzerland, February 21, 2011 - Cytos Biotechnology
Ltd (SIX: CYTN) announced today that it has received European Union funding
to work in a scientific consortium with the goal of preventing and treating
infections caused by emerging viral pathogens deemed to be of threat to
Europe. The consortium, known as VECTORIE, is funded by the European
Commission Framework Program 7 (Grant # 261466) and will employ a
multidisciplinary approach involving virology, entomology and advanced
vaccinology. Cytos' Biotechnology VLP platform has been selected to
generate vaccine candidates which will be tested in disease models.
Dr Martin Bachmann, CSO of Cytos Biotechnology commented 'We are very much
looking forward to participating in this exciting collaboration and
potentially providing novel intervention strategies to help prepare Europe
against the threat of emerging viral diseases. This program, together with
our recently announced partnerships with the NIH and A*STAR in Malaria and
Influenza respectively, exemplifies the broad recognition and appeal of our
VLP platform technology'.
For further information please contact:
Wolfgang A. Renner, PhD
Chief Executive Officer
Cytos Biotechnology Ltd
Phone: +41 44 733 47 03
Fax: +41 44 733 47 04
e-Mail: wolfgang.renner(at)cytos.com
Website: www.cytos.com
About Cytos Biotechnology
Cytos Biotechnology Ltd is a public Swiss biotechnology company that
specializes in the discovery, development and commercialization of a new
class of biopharmaceutical products - the Immunodrugs(TM). Immunodrugs(TM)
are intended for use in the treatment and prevention of common chronic
diseases, which afflict millions of people worldwide. Immunodrugs(TM) are
designed to instruct the patient's immune system to produce desired
therapeutic antibody or T cell responses that modulate chronic disease
processes. Taking advantage of the high flexibility of its Immunodrug(TM)
platform, Cytos Biotechnology has built a diversified pipeline of
Immunodrug(TM) candidates in various disease areas, of which five are
currently in clinical development. The Immunodrug(TM) candidates are
developed both in-house and together with Novartis, Pfizer and Pfizer
Animal Health. Founded in 1995 as a spinoff from the Swiss Federal
Institute of Technology (ETH) in Zurich, the Company is located in
Schlieren (Zurich). Currently, the Company has 77 full-time equivalents.
Cytos Biotechnology Ltd is listed on the main segment at the SIX Swiss
Exchange (SIX:CYTN).
This foregoing press release may contain forward-looking statements that
include words or phrases such as 'may', 'will', 'has been selected',
'providing', 'designed', 'intend' or other similar expressions. These
forward-looking statements are subject to a variety of significant
uncertainties, including scientific, business, economic and financial
factors, and therefore actual results may differ significantly from those
presented. There can be no assurance that any further therapeutic entities
will enter clinical trials, that clinical trial results will be predictive
for future results, that therapeutic entities will be the subject of
filings for regulatory approval, that any drug candidates will receive
marketing approval from the U.S. Food and Drug Administration or equivalent
regulatory authorities, or that drugs will be marketed successfully.
Against the background of these uncertainties readers should not rely on
forward-looking statements. The company assumes no responsibility to update
forward-looking statements or adapt them to future events or developments.
This document does not constitute an offer or invitation to subscribe or
purchase any securities of Cytos Biotechnology Ltd.
End of Corporate News
---------------------------------------------------------------------
21.02.2011 News transmitted by EquityStory AG.
The issuer is responsible for the contents of the release.
EquityStory publishes regulatory releases, media releases on the
capital market and press releases.
The EquityStory Group distributes authentic and real-time financial
news for over 1'300 listed companies.
The Swiss news archive can be found at
http://www.equitystory.ch/nachrichten
---------------------------------------------------------------------
Language: English
Company: Cytos Biotechnology AG
Wagistr. 25
8952 Schlieren
Schweiz
Phone: +41 44 733 4747
Fax: +41 44 733 4740
E-mail: info(at)cytos.com
Internet: www.cytos.com
ISIN: CH0011025217, CH0029060735
Swiss Security Number: -
Listed: Regulierter Markt in SIX; Freiverkehr in
Berlin, München, Stuttgart; Open Market in
Frankfurt
End of News EquityStory AG News-Service
---------------------------------------------------------------------
112724 21.02.2011
Datum: 21.02.2011 - 07:00 Uhr
Sprache: Deutsch
News-ID 33246
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 232 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Cytos Biotechnology receives EU funding to work on novel vaccine approaches for emerging viral diseases"
steht unter der journalistisch-redaktionellen Verantwortung von
Cytos Biotechnology AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
